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SUMMARY 
Background: As access to antiretroviral therapy 
(ART) increases, the emergence and transmission of 
HIV drug resistant strains becomes a major problem.  
The World Health Organization (WHO) therefore rec-
ommends an initial minimum-resource method to sig-
nal when transmitted HIV drug resistance (HIVDR) 
requires action.  
Objective: This survey sought to generate information 
on the presence of HIV drug-resistant strains in the 
locality where Ghana’s ART for HIV was first intro-
duced. 
Methods: The Ghana HIVDR threshold survey (TS) 
was conducted and analyzed according to WHO strate-
gy for surveillance of HIVDR in the Eastern Region of 
Ghana. Sixty (60) plasma specimens were collected 
from 2007 to 2009 by an unlinked anonymous method 
from HIV seropositive pregnant women, aged between 
15 to24 years, who were with their first pregnancy and 
ART naive. Genotyping was done as follows; Ribonu-
cleic acid (RNA) was extracted from the samples and 
the protease (PR) and reverse transcriptase (RT) genes 
amplified and sequenced. The sequences were then 
analyzed for HIV drug resistance mutations using Stan-
ford University HIV Drug Resistance Database.  
Results: Only two individuals were found with major 
HIVDR mutations: one each in the PR and RT genes. 
Thus the level of HIVDR in the study population in 
2009 was classified as low (< 5%). 
Conclusion: As at February 2009, transmitted drug 
resistance was not a serious problem in the Eastern 
Region of Ghana. However, it is important to continue 
monitoring tHIVDR in order to understand the dynam-




Combination antiretroviral therapy (ART) is known to 
improve treatment in HIV infected persons but the 
emergence of drug resistant viral strains is an obstacle 
in the effective management of HIV infection and 
AIDS.  
Resistant strains may develop through selective pres-
sure during ART or from spontaneously generated pol-
ymorphisms in rare cases. However, drug naïve per-
sons could also be infected with drug-resistant strains.1 
Transmitted HIV drug resistance (tHIVDR) is therefore 
a major concern as it increases the risk of virologic 
failure.1 This is particularly relevant in resource limited 
settings where treatment options are limited. Persons 
with tHIVDR commence therapy with a lower genetic 
barrier to resistance, higher risk of virologic failure and 
a higher risk of developing resistance to drugs in the 
regimen that they were originally susceptible to.2-5 Ef-
forts to improve treatment outcomes and reduce trans-
mission of HIV through the optimal delivery of ART 
and HIV prevention programmes must be accompanied 
by on going evaluations of HIV drug resistance.6  
 
An essential element in the evaluation of the HIV situa-
tion is the population-based surveillance of tHIVDR in 
recently infected individuals.6 This will provide infor-
mation to public health bodies to design educative and 
prevention programs and to inform the rational use of 
antiretroviral drugs by treatment programs, clinicians 
and policy makers. The prevalence of tHIVDR will 
probably remain low for several years in most coun-
tries where ART is being rapidly scaled up. The World 
Health Organization (WHO) therefore recommends an 
initial minimum-resource method to signal when 
transmitted HIVDR requires action.7  
 
ART was introduced to Ghana in 2003. The program 
has been rapidly scaled up with an estimated 42,000 
patients on ART in 141 care centres at the end of 
2010.8 Ghana does not have adequate resources to 
monitor all persons on ART with viral load and drug 
resistance testing. Thus there was a need for popula-
tion-based surveillance of HIVDR to evaluate the ART 
program to improve the outcome of the national treat-










The objective of this first ever threshold survey in 
Ghana was to generate information on active transmis-
sion of HIV drug-resistant strains in drug-naïve persons 
in the country.   
 
METHODS  
The Ghana HIVDR threshold survey was conducted 
and analyzed based on the World Health Organization 
(WHO) strategy for surveillance of transmitted HIVDR 
in resource limited settings. The details of the WHO 
strategy are previously discussed.6 Antenatal clients, 
with their first pregnancy, were used as proxy group of 
persons with recent HIV infections. The study protocol 
was reviewed and approved by the Ghana Health Ser-
vices Ethical Review Committee. 
 
Study area and population  
Two ART sites in the Eastern Region of Ghana were 
used in this survey. The sites, located at the Atua Gov-
ernment Hospital and St. Martins de Porres Hospital, 
Agomanya, were selected because they were the pilot 
sites for the introduction of ART in 2003. These health 
facilities are national HIV sentinel survey sites and the 
HIV prevalence in the district indicated a reasonable 
sampling time. Pregnant women who were HIV-1 se-
ropositive but ART-naïve, aged between 15 to 24 
years, with their first pregnancy were enrolled into the 
study after obtaining their informed consent.  
 
Sample collection and processing 
The unlinked anonymous sampling method was used to 
collect blood samples from 60 eligible antenatal clinic 
clients who accessed Prevention of Mother-to-Child 
Transmission (PMTCT) of HIV services at the two 
sites from October 2007 to February 2009. Blood sam-
ples were processed into plasma at the collection point. 
The plasma was divided into aliquots of 0.5ml each 
and transported to the Public Health and Reference 
Laboratory (PHRL) in Accra in cold boxes.  Specimens 
were accompanied by a form with sample identification 
number, date of blood collection and the number of 
vials attached. The PHRL conducted serology HIV 
testing by the Inno-lia HIV I/II (Innogenetics, Bel-
gium) to determine the type of HIV infection. Three 
aliquots of specimens were then transported to the No-
guchi Memorial Institute for Medical Research 
(NMIMR) and stored at -80oC until genotypic analysis 
was performed.  
 
Genotyping 
Viral ribonucleic acid (RNA) was extracted from 140 
µl of plasma using the QIAamp Viral RNA Kit (QI-
AGEN, GmbH, Germany) according to the manufac-
turer’s protocol. The viral load of the samples was es-
timated by an in-house real-time PCR assay using 
Taqman RT-RCR reagents (Applied Biosystems, Fos-
ter City, CA, USA) in an ABI 7300 Real Time PCR 
System. The protease (PR) and reverse transcriptase 
(RT) -coding genes were amplified in separate reac-
tions using gene-specific primers as previously pub-
lished.11 The one-step RT-PCR kit (QIAGEN, GmbH, 
Germany) was used for the RT-PCR step [50oC 30min, 
95o 15min, 40 cycles of (94oC 30sec, 55oC 1min, 72oC 
90s), 72oC 7min] and the AmpliTaq Gold PCR Master 
Mix Kit (Applied Biosystems, Foster City, CA, USA) 
was used in a nested PCR [ 94o 2min, 40 cycles of 
(94oC 30sec, 56oC 1min, 72oC 1min), 72oC 7min]. The 
positive PCR products were purified using QIAquick 
PCR purification kit (QIAGEN, GmbH, Germany) and 
sequenced. All PCR reactions were performed in the 
GeneAmp PCR System 2700 (Applied Biosystems, 
Foster City, CA, USA).  The Big Dye Terminator cycle 
sequencing kit vs 3.1 (Applied Biosystems) was used. 
The cycle conditions were 94oC for 2mins followed by 
25 cycles of 94oC for 30sec, 50oC for 15sec and 60oC 
4mins. Sequence analysis was done in an ABI 3130 
Genetic Analyzer (Applied Biosystems, Foster City, 
CA, USA). The sequence data was initially viewed and 
edited using DNA Sequencing Analysis Software 5.1 
(Applied Biosystems Foster City, CA, USA). The se-
quences were then aligned using BioEdit software (Ibis 
Biosciences, Carlsbad, CA) and FASTA- formatted. 
The FASTA-formatted sequences were then submitted 
online to the Stanford University HIV Drug Resistance 
Database to generate mutation list, HIVDR and sub-
type information. The resulting mutation list was com-
pared with the WHO mutation list for HIVDR surveil-
lance.9,10 
 
Drug Resistance Mutation Analysis 
HIVDR prevalence was categorized using the WHO 
TS binomial sequential sampling method.7 The details 
of the WHO protocol of determining HIVDR preva-
lence for threshold surveys was previously published.7 
The specimens were listed in order of date of blood 
draw from the older to the newer specimens and the 
genotype results were examined. The “running total” of 
specimens with major HIVDR mutations was recorded 
and compared to the WHO recommendations. A classi-
fication of HIVDR prevalence was made based on the 
running total of specimens with major HIVDR muta-
tions. A predetermined lower limit (LL) and upper lim-
it (UL) were used for determining the prevalence. The 
prevalence of HIVDR was classified as ≤ 5% if the 
total number of specimens with mutations was less 
than the LL and as ≥15% if the running total of speci-
mens with mutations was higher than the UL. If a total 
of 47 specimens were genotyped and the running total 
of specimens with major HIVDR mutations was neither 
less than the LL nor greater than the UL, prevalence 









External Quality Control 
One aliquot of plasma (0.5ml), for each of the 60 sam-
ples, was shipped on dry ice from the NMIMR, Ghana 
to the AIDS Virus Research Unit of National Institute 
for Communicable Diseases (NICD), Johannesburg, 
South Africa for quality assurance purposes. The sam-
ples were re-analyzed using an in-house (WHO-
accredited) HIV genotyping protocol certified by the 
Virology Quality Assurance Program. 
 
RESULTS  
Of the 60 specimens analyzed, 53 were successfully 
sequenced for the RT gene. Seven samples could not 
be amplified. The first 47 samples were analyzed in 
line with the WHO recommendations for classifying 
the prevalence of transmitted HIVDR.7 One specimen 
(AGDR37) was found to have the mutations M184V 
and Y181C as shown in Table 1. These are major 
HIVDR mutations as described on the WHO surveil-
lance list.9, 10 Genotyping results from NICD corrobo-
rated the NMIMR analyses. The same mutations 
(M184V and Y181C) were found in the RT gene of 
sample AGDR37 from the independent analyses done 
in both institutions. Forty-six samples were successful-
ly sequenced in the PR gene. Out of these, one sample 
had the mutation M46L as shown in Table 2. This is a 
major mutation that was recently added to the surveil-
lance list for tHIVDR.9 The Stanford Database also 
classified most of the specimens as subtype 
CRF02_AG (74%) with 26% being subtypes A, G, K 
or CRF01_AE. Fourteen of the samples had viral loads 
below the detection limit of the assay (400 copies/ml) 
and those with detectable viral loads ranged from 503 
to 315, 063 copies/ml. 
 
Table 1 Major and minor HIVDR mutations found in the RT gene in specimens collected from HIV-1 seropositive 
ART-naïve pregnant women in the Eastern Region of Ghana (2007-2009) 
Sample ID Major DR Mutation Minor DR mutation 
AGDR4 NONE E138Q 
AGDR12 NONE K101Q 
AGDR35 NONE K103R 
AGDR37 M184V, Y181C NONE 
AGDR41 NONE A98G 
 
A98G is a minor mutation that reduces Nevirapine susceptibility by 2 to 3-fold. It is selected by Nucleoside Reverse Transcrip-
tase Inhibitors (NRTIs) and Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs). K101Q is weakly associated with 
NNRTI therapy and minimally reduces susceptibility to each of the NNRTIs. 
K103R occurs in about 1%-2% of untreated persons and by itself has no effect on NNRTI susceptibility.  
E138Q is weakly associated with NNRTI therapy. It may contribute to decreased NNRTI susceptibility in certain genetic con-
texts. 
 
Table 2 Major and minor HIVDR mutations found in the PR gene in specimens collected from HIV-1 seropositive 
ART-naïve pregnant women in the Eastern Region of Ghana (2007-2009) 
Sample ID Major DR Mutation Minor DR mutation 
AGDR5 NONE V11I 
ATDR62 NONE L10I 
ATDR63 NONE L10I 
AGDR9 NONE N83D 
AGDR12 NONE L10I 
ATDR14 NONE L10V 
AGDR21 NONE V11I 
AGDR24 NONE I50F 
ATDR23 NONE D30G 
AGDR32 NONE L10I 
AGDR34 M46L I84L 
D30G is a highly unusual mutation at this position 
L10I/V is known to occur in 5-10% of untreated persons. 
M46L decreases susceptibility to the Protease Inhibitors (PIs) but only when it is present with other relevant mutations.  
I84L is a highly unusual mutation at this position and it is not yet implicated in resistance to PIs. 
N83D is a non-polymorphic mutation that occurs more commonly in heavily treated patients. It has been associated with de-
creased virological response to TPV/r. Its effect on other PIs is not known 










The list of mutations used for the interpretation of re-
sults was those published in the Surveillance Drug Re-
sistance Mutation (SDRM) worksheet.9 After analyzing 
the required numbers of sample, as prescribed by the 
WHO,7 one sample each showed resistance mutations 
in the RT and PR genes.  Minor mutations were also 
seen in the samples analyzed as shown in Table 1 and 
Table 2. The minor mutations observed in the RT gene 
included E138Q, K101Q, K103R and A98G while 
those observed in the PR gene included L10I/V, V11I, 
N83D, I50F, D30G and I84L. These do not confer drug 
resistance by themselves and were not listed on the 
SDRM. The level of tHIVDR in the study population 
was therefore classified as low (< 5%). These speci-
mens were collected from the pilot sites where ART 
was first introduced in Ghana in 2003 and so represent 
a population that has the longest experience with ART 
in Ghana.  
 
The low leel of tHIVDR observed in this population is 
an indication that the 1st and 2nd line drug regimens 
should be beneficial to patients who are yet to start 
treatment. Similar studies in Ethiopia and Malawi have 
reported low levels of tHIVDR.12, 13 Another study in 
treatment-naïve HIV infected individuals in Ghana, 
previously reported the absence of major drug re-
sistance mutations in either the RT or the PR genes.14 
However, one study done in East and Southern Africa 
described increasing trends of tHIVDR over a 4 year 
period and another from four countries in Central Afri-
ca reported low (<5%) to medium (5%-15%) preva-
lence of tHIVDR1,15 The low tHIVDR level observed 
in this study calls for continuous monitoring of 
tHIVDR. This study should be repeated after 2 years at 
the same sites and later extended to other sites for a 
continuous assessment of tHIVDR in Ghana 
 
CONCLUSION 
The level of tHIVDR in the Eastern Region of Ghana 
in 2009 could be classified as low (≤ 5%). However, it 
is important to continue monitoring tHIVDR in order 
to understand the dynamics of the evolution of HIV 
drug resistance in the country. An HIV genotyping 
laboratory has been established at the NMIMR to en-
hance the local capacity to conduct HIVDR testing in 
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